William Blair & Company’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.1M | Sell |
371,119
-52,845
| -12% | -$1.7M | 0.03% | 322 |
|
|
2025
Q4 | $14.9M | Buy |
423,964
+68,038
| +19% | +$2.41M | 0.04% | 285 |
|
|
2025
Q3 | $9.35M | Buy |
355,926
+25,919
| +8% | +$773K | 0.02% | 377 |
|
|
2025
Q2 | $8.75M | Buy |
330,007
+21,442
| +7% | +$564K | 0.02% | 375 |
|
|
2025
Q1 | $7.45M | Buy |
308,565
+36,696
| +13% | +$1.16M | 0.02% | 388 |
|
|
2024
Q4 | $10.9M | Buy |
271,869
+44,915
| +20% | +$2.56M | 0.03% | 323 |
|
|
2024
Q3 | $14.4M | Buy |
226,954
+125,747
| +124% | +$7.38M | 0.04% | 290 |
|
|
2024
Q2 | $5.36M | Sell |
101,207
-198,028
| -66% | -$13M | 0.02% | 470 |
|
|
2024
Q1 | $24.5M | Buy |
299,235
+240,863
| +413% | +$10.7M | 0.08% | 187 |
|
|
2023
Q4 | $1.09M | Sell |
58,372
-32,173
| -36% | -$421K | ﹤0.01% | 830 |
|
|
2023
Q3 | $1M | Sell |
90,545
-26,334
| -23% | -$377K | ﹤0.01% | 833 |
|
|
2023
Q2 | $1.89M | Buy |
116,879
+8,934
| +8% | +$187K | 0.01% | 678 |
|
|
2023
Q1 | $1.8M | Buy |
107,945
+74,788
| +226% | +$773K | 0.01% | 680 |
|
|
2022
Q4 | $312K | Sell |
33,157
-80,631
| -71% | -$360K | ﹤0.01% | 1213 |
|
|
2022
Q3 | $310K | Sell |
113,788
-45,130
| -28% | -$148K | ﹤0.01% | 1216 |
|
|
2022
Q2 | $459K | Sell |
158,918
-799
| -0.5% | -$1.98K | ﹤0.01% | 1095 |
|
|
2022
Q1 | $479K | Buy |
159,717
+6,454
| +4% | +$23.2K | ﹤0.01% | 1170 |
|
|
2021
Q4 | $705K | Buy |
153,263
+8,082
| +6% | +$45.3K | ﹤0.01% | 1082 |
|
|
2021
Q3 | $912K | Sell |
145,181
-11,555
| -7% | -$71.4K | ﹤0.01% | 966 |
|
|
2021
Q2 | $939K | Buy |
156,736
+3,000
| +2% | +$17.8K | ﹤0.01% | 940 |
|
|
2021
Q1 | $972K | Buy |
153,736
+6,910
| +5% | +$48.6K | ﹤0.01% | 908 |
|
|
2020
Q4 | $827K | Buy |
146,826
+37,425
| +34% | +$227K | ﹤0.01% | 923 |
|
|
2020
Q3 | $637K | Buy |
109,401
+36,335
| +50% | +$250K | ﹤0.01% | 902 |
|
|
2020
Q2 | $527K | Sell |
73,066
-1,500
| -2% | -$9.96K | ﹤0.01% | 926 |
|
|
2020
Q1 | $349K | Sell |
74,566
-15,255
| -17% | -$93.8K | ﹤0.01% | 972 |
|
|
2019
Q4 | $720K | Sell |
89,821
-60,487
| -40% | -$441K | ﹤0.01% | 870 |
|
|
2019
Q3 | $1.03M | Sell |
150,308
-8,150
| -5% | -$60.5K | 0.01% | 737 |
|
|
2019
Q2 | $1.31M | Sell |
158,458
-4,825
| -3% | -$41.2K | 0.01% | 691 |
|
|
2019
Q1 | $1.62M | Buy |
163,283
+1,453
| +0.9% | +$12.2K | 0.01% | 616 |
|
|
2018
Q4 | $1.24M | Buy |
161,830
+156,330
| +2,842% | +$1.87M | 0.01% | 633 |
|
|
2018
Q3 | $96K | Buy |
5,500
+500
| +10% | +$5.95K | ﹤0.01% | 1382 |
|
|
2018
Q2 | $47K | Buy |
+5,000
| New | +$33.3K | ﹤0.01% | 1426 |
|
Other funds holding VKTX
VCM
VPM
William Blair & Company's VKTX Position: Q1 2026 in Review
William Blair & Company reduced its Viking Therapeutics (VKTX) stake by 12% in Q1 2026, selling an estimated $1.7M and leaving 371,119 shares worth $12.1M. The position accounts for 0.03% of the portfolio, ranked #322.
William Blair & Company first reported a position in VKTX in Q2 2018 and has held it in 32 quarters since. The position peaked at $24.5M in Q1 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- William Blair & Company held 371,119 shares of Viking Therapeutics worth $12.1M as of Q1 2026.
- William Blair & Company sold 52,845 Viking Therapeutics shares in Q1 2026, an estimated $1.7M.
- Viking Therapeutics made up 0.03% of William Blair & Company's portfolio in Q1 2026, its #322 holding.
- William Blair & Company first reported a position in Viking Therapeutics in Q2 2018 and has held it in 32 quarters since.
- William Blair & Company's Viking Therapeutics position peaked at $24.5M in Q1 2024.
- 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.